poisar

Stocks · News reference

Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29

Benzinga Newsdesk

Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $29.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RLAY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

    Relay Therapeutics announced that management will participate in fireside chats at the Wells Fargo Healthcare Conference on September 8, 2026 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The clinical-stage precision medicine company is developing therapies for cancer and genetic diseases, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer.

    RLAY